Takeda Pharmaceutical Company Limited
TKPHF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $4,581,551 | $4,263,762 | $4,027,478 | $3,569,006 |
| % Growth | 7.5% | 5.9% | 12.8% | – |
| Cost of Goods Sold | $1,580,217 | $1,431,505 | $1,244,072 | $1,106,846 |
| Gross Profit | $3,001,334 | $2,832,257 | $2,783,406 | $2,462,160 |
| % Margin | 65.5% | 66.4% | 69.1% | 69% |
| R&D Expenses | $730,227 | $729,924 | $633,325 | $526,087 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,104,766 | $1,053,819 | $997,309 | $886,361 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $823,755 | $834,439 | -$9,466 | -$20,723 |
| Operating Expenses | $2,658,748 | $2,618,182 | $2,292,900 | $2,001,315 |
| Operating Income | $342,586 | $214,075 | $490,505 | $460,844 |
| % Margin | 7.5% | 5% | 12.2% | 12.9% |
| Other Income/Exp. Net | -$167,502 | -$161,284 | -$115,415 | -$158,273 |
| Pre-Tax Income | $175,084 | $52,791 | $375,090 | $302,571 |
| Tax Expense | $66,941 | -$91,406 | $58,052 | $72,405 |
| Net Income | $107,928 | $144,067 | $317,017 | $230,059 |
| % Margin | 2.4% | 3.4% | 7.9% | 6.4% |
| EPS | 68.36 | 92.09 | 204.29 | 147.14 |
| % Growth | -25.8% | -54.9% | 38.8% | – |
| EPS Diluted | 67.23 | 91.16 | 201.94 | 145.87 |
| Weighted Avg Shares Out | 1,579 | 1,564 | 1,552 | 1,564 |
| Weighted Avg Shares Out Dil | 1,605 | 1,580 | 1,570 | 1,577 |
| Supplemental Information | – | – | – | – |
| Interest Income | $19,638 | $11,293 | $62,913 | $23,700 |
| Interest Expense | $137,311 | $119,535 | $169,698 | $166,607 |
| Depreciation & Amortization | $761,396 | $728,002 | $664,400 | $583,151 |
| EBITDA | $1,073,791 | $900,328 | $1,156,463 | $1,008,154 |
| % Margin | 23.4% | 21.1% | 28.7% | 28.2% |